News Releases News Releases Year None20202019201820172016 Nov 11, 2020 Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2 Nov 09, 2020 Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2 Oct 29, 2020 Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection Oct 14, 2020 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients Oct 12, 2020 Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies Oct 09, 2020 Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released Oct 07, 2020 Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID Oct 07, 2020 Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 Oct 04, 2020 Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline Sep 30, 2020 Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last » Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
News Releases Year None20202019201820172016 Nov 11, 2020 Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2 Nov 09, 2020 Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2 Oct 29, 2020 Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection Oct 14, 2020 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients Oct 12, 2020 Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies Oct 09, 2020 Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released Oct 07, 2020 Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID Oct 07, 2020 Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 Oct 04, 2020 Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline Sep 30, 2020 Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last »
Nov 11, 2020 Sorrento Announces IND Filing for COVI-DROPS, an Intranasal Formulation of a High Potency Neutralizing Antibody Against SARS-CoV-2
Nov 09, 2020 Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
Oct 29, 2020 Sorrento Announces That Intranasal Administration of COVI-AMG™ Neutralizing Antibody Prevented COVID-19 Disease Progression in Infected Hamsters Following SARS-CoV-2 Infection
Oct 14, 2020 Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
Oct 12, 2020 Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
Oct 07, 2020 Sorrento Announces the Discovery of Salicyn-30 Small Molecule That Strongly Inhibits SARS-CoV-2 Infection in Preclinical Studies and Highlights its Place in a Potential Multi-Modal Therapy Strategy in Combination With Neutralizing Antibodies Against COVID
Oct 07, 2020 Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020
Sep 30, 2020 Sorrento Therapeutics and ViralClear Enter Into Agreement to Explore Combination Antibody Plus Antiviral Therapy Against COVID-19
